MK 217

Key Product Details

Product Description

Osteoclast-mediated bone resorption inhibitor. Binds and blocks farnesyl diphosphate synthase (FPPS) in the HMG-CoA pathway (IC₅₀ = 460 nM for recombinant human FPPS); causes macrophage apoptosis. Inhibits prenylation and sterol biosynthesis in purified osteoclasts.

Product Specifications for MK 217

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for MK 217

The following data is based on the product molecular weight 271.08.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	7.38 mL	36.89 mL	73.78 mL
2.5 mM	1.48 mL	7.38 mL	14.76 mL
5 mM	0.74 mL	3.69 mL	7.38 mL
25 mM	0.15 mL	0.74 mL	1.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Fournier Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vitro. Cancer Res. 2008 PMID: 18974139
• Fisher Alendronate mechanism of action; geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc.Natl.Acad.Sci.
• Bergstrom Alendronate is a specific, nanomolar inhibitor of fanesyl diphosphate synthase. Arch.Biochem.Biophys. 2000 PMID: 10620343

Product Documents for MK 217